Osmotica Pharmaceuticals (OSMT)

A tiny company and speculative. Some months ago, they had a tired, but profitable portfolio of generic and profitable drugs that produced a stream of cash. They invested that cash to treat droopy eyelid, with a goal to be a less-generic drug company and more branded. Then they tested an MS-related drug, but shelved it which hurt the stock. Two months, the FDA approved the droopy eyelid drug which pushed the stock higher. Then they made a secondary offering which didn't meet demand and the stock pulled back.

A tiny company and speculative. Some months ago, they had a tired, but profitable portfolio of generic and profitable drugs that produced a stream of cash. They invested that cash to treat droopy eyelid, with a goal to be a less-generic drug company and more branded. Then they tested an MS-related drug, but shelved it which hurt the stock. Two months, the FDA approved the droopy eyelid drug which pushed the stock higher. Then they made a secondary offering which didn't meet demand and the stock pulled back.